Quantification of Cognitive Process Degradation While Mobile, Attributable to the Environmental Stressors Endurance, Vibration, and Noise

Schipani, Salvatore P.; Bruno, Richard S.; Lattin, Michael A.; King, Bobby M.; Patton, Debra J.

doi:10.1037/e444002005-001

Cited by 6 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Motion sickness in a command and control vehicle (C2V) has been investigated by Cowings et al 9) , who found that while incidences of emesis were rare, many of the subjects reported drowsiness and mild nausea. Performance on cognitive tasks in a C2V has also been studied [10][11][12] , but the results have been ambiguous. In these studies, the details of the vibration spectra were not reported.…”

Section: Introductionmentioning

confidence: 99%

Measurement of Noise and Vibration in Canadian Forces Armoured Vehicles

2007

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Measurement of Noise and Vibration in Canadian Forces Armoured Vehicles

2007

View full text Add to dashboard Cite

“…Sherwood and Griffin (1992) found some differences in the rates of learning between two groups, a vibration group and a static group. Schipani et al (1998) found differences in a cognitive battery performance in areas such as time sharing, selective attention, inductive reasoning, memorization, and spatial orientation after exposure to rides in a modified M113. The effect of ride motion on cognitive functioning is an area where more information is needed.…”

Section: Cognitive Functionsmentioning

confidence: 99%

“…Other studies of performance in moving vehicles have shown performance decrements and sometimes motion sickness symptoms. For example, in a modified M113, cognitive task performance was less accurate (7 to 46%) and slower (7 to 40%) during moving operations (Schipani et al, 1998 ). Another study showed that, in a moving amphibious assault vehicle, 74% of the Marines tested reported moderate to severe motion sickness symptoms after working at computer workstations (Rickert, 2000).…”

Section: Introductionmentioning

confidence: 99%

Soldier Performance Issues in C2 `On the Move'

Hill¹,

Tauson²

2005

View full text Add to dashboard Cite

Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. ABSTRACTFor several years, the need for increased mobility for command and control (C2) assets in U.S. ground forces has been apparent. However, increased use of automated information systems in moving vehicles does incur a price in Soldier performance. There are many Soldier performance issues associated with the performance of tasks while the vehicle is moving, that is, "on the move." This paper presents some of the issues related to the effects of vehicle motion on Soldier performance. The issues include vibration, visual displays, manual control, interactions among Soldiers, cognitive functions, and workload. Four areas of mitigation for vehicle motion effects are identified and briefly discussed. BACKGROUND

show abstract

Section: Impact Of Motion Sickness On the Military And Astronautsmentioning

confidence: 99%

“…Finally, in recent studies examining military land maneuvers in amphibious assault vehicles, 74% of Marines reported moderate to severe symptoms, such as headache, nausea, malaise, anorexia, and emesis, while working at computer workstations (Cowings, Toscano, & DeRoshia, 1998;Cowings, Toscano, DeRoshia & Tauson, 1999;Rickert, 2000). Rickert (2000) and Schipani, Bruno, Lattin, King and Patton (1998) demonstrated that military personnel conducting mission operations in this provocative motion environment exhibited significant performance decrements on cognitive tasks requiring time sharing, selective attention, inductive reasoning, memorization and spatial orientation.Motion sickness in dynamic operational environments is not limited to the military. Data collected from Space Shuttle missions report 70-80% of astronauts suffer from Space Adaptation Syndrome (or space motion sickness) during the first 2-3 days in microgravity and many suffer from post-flight readaptation sickness upon return to Earth (Davis, Vanderploeg, Santy, Jenning & Stewart, 1988;Heer & Paloski, 2006;Reschke et al, 1998).…”

mentioning

confidence: 99%

A Comparison of Intranasal and Oral Scopolamine for Motion Sickness Prevention in Military Personnel

Simmons¹,

Phillips²,

Lojewski³

et al. 2008

View full text Add to dashboard Cite

Executive SummaryMotion sickness in astronauts, aviators, and military personnel often leads to decrements in operational performance. The anti-motion sickness medication, scopolamine, is effective; however, oral and transdermal administrations have proven problematic due to slow absorption, low bioavailability, unpredictable therapeutic effect, potential medication loss due to emesis, and side effects. Although efficacy and side-effect characteristics of intranasally administered scopolamine have not been established, results from preliminary studies indicate intranasal scopolamine has faster absorption, higher bioavailability, and a more reliable therapeutic index than equivalent oral or transdermal forms. The purpose of this study was to compare the efficacy, side-effect profile, and pharmacotherapeutics of a 0.4 mg dose of intranasal scopolamine gel and a 0.8 mg dose of oral scopolamine. It was hypothesized that intranasal delivery of scopolamine would rapidly achieve therapeutic concentrations at lower doses compared to oral scopolamine while minimizing medication-induced performance impairment. To test these hypotheses, 54 aviation candidates, 50 male and 4 female, were recruited and randomized to one of three treatment groups [intranasal scopolamine gel (IN SCOP); oral scopolamine (PO SCOP); or placebo] and then exposed to passive Coriolis cross-coupling for 40 minutes or until moderate nausea was reported. Medication efficacy was determined by number of head movements tolerated among groups and pharmacotherapeutics for IN SCOP and PO SCOP were determined by salivary assay. Side-effect profiles for all groups were derived from performance on a cognitive battery, measurements of near-focus visual accommodation (VA), scores on the Karolinska Sleepiness Scale (KSS) and motion sickness questionnaires. Analysis detected no significant differences in the number of head movements tolerated among groups, p > 0.05. Pharmacotherapeutic data show increased scopolamine absorption and decreased time to reach maximum salivary concentration with intranasal administration (T max = 1.463 ± 0.98 hr, C max = 54.857± 103.739 ng/mL, AUC = 51.732 ± 93.802 ng*h/mL). No treatment effects were detected over time on the cognitive battery, VA, or KSS, p > 0.05. An ANOVA revealed a significant decrease in heart rate over time for IN SCOP and PO SCOP versus placebo at several time points post-dose, while no clinically significant differences were found for systolic or diastolic blood pressures. A negative linear relationship was found between Motion Sickness Susceptibility Questionnaire (MSSQ) scores and number of head movements (r = -.24, p < .05). The present study lacked sufficient power to draw definitive conclusions regarding efficacy or to make adequate comparisons between the two medications, F (2, 50) = 0.743, p > .05, observed power = 17 %, however; medication absorption was significantly greater for IN SCOP at onehalf the dose (0.4 mg v. 0.8 mg) with no side effects or detrimental impact to performance. 3 Introduction Impac...

show abstract

Quantification of Cognitive Process Degradation While Mobile, Attributable to the Environmental Stressors Endurance, Vibration, and Noise

Cited by 6 publications

References 0 publications

Measurement of Noise and Vibration in Canadian Forces Armoured Vehicles

Measurement of Noise and Vibration in Canadian Forces Armoured Vehicles

Soldier Performance Issues in C2 `On the Move'

A Comparison of Intranasal and Oral Scopolamine for Motion Sickness Prevention in Military Personnel

Contact Info

Product

Resources

About